MILWAUKEE, Sept. 1, 2015 /PRNewswire/ -- The Dohmen Company today announced the appointment of Eric Floyd, Ph.D., MBA as Chief Science Officer (CSO) of Dohmen Life Science Services (DLSS). In this newly created role, Dr. Floyd will lead Dohmen's growing regulatory consulting practice as well as a portfolio of pre-commercial and post approval outsourced services in quality, regulatory, pharmacovigilence, REMS, medical affairs and medical communications. Dr. Floyd brings decades of experience leading global regulatory affairs and quality assurance divisions within Novartis, Cephalon, Hospira and, most recently, Lundbeck; as well as in-depth knowledge of the US Food and Drug Administration and navigating regulatory bodies worldwide.
"This area of expertise is of particular strategic focus for Dohmen. As precision medicine begins to take root, with continued interest and investment in the rare disease space, we can see the ripple effect in all aspects of development and commercialization. We've invested heavily, on behalf of our life science clients, in best practice tools, technology and talent in support of this sea of change. Serving small markets requires a different strategic approach to the marketplace, starting with clinical trial design and continuing through the product's lifecycle," said Cynthia LaConte, CEO of Dohmen. "Eric's experience with global regulators in pharma, bio and in particular within the orphan drug space will help our clients navigate new paradigms for development, clinical trial and ongoing safety requirements."
With both an MBA and Ph.D. in Neurophysiology, Dr. Floyd joins Dohmen after serving as vice president of U.S. regulatory affairs and clinical quality assurance and vice president of global regulatory affairs at Lundbeck, Inc. Prior to his time at Lundbeck, he was vice president of worldwide regulatory affairs at Cephalon, Inc. and was vice president and global head of respiratory, dermatology and tropical medicines drug regulatory affairs at Novartis. Dr. Floyd has also worked in global regulatory affairs at Aventis Pharmaceuticals, Bristol-Myers Squibb Co. and Merck Research Laboratories.
"The opportunity that lies ahead for DLSS is tremendous. Dohmen has built a strong portfolio of capability in response to changing industry dynamics. They're clearly on the leading edge of that change with services that span a product's journey from clinical trial to patient care. I'll be focused on advancing the compliance business unit with a diverse array of services that range from pre-commercial consulting to in market call center support. I'm looking forward to leveraging the reputational excellence of a brand that's been in market for over 157 years and providing the innovation that our customers expect from us," said Eric Floyd, Ph.D. and chief science officer of Dohmen Life Science Services. "It's a pleasure to find an organization where I can use my knowledge and experience to advance the DLSS mission of reducing the burden of disease by connecting life science innovators with the patients they serve."
About Dohmen: Headquartered in Milwaukee, Wisconsin, Dohmen has been finding ways to create an efficient, effective and easy to use healthcare experience since 1858; first as an apothecary, then as a manufacturer, later as a wholesaler and today as the parent company of Dohmen Life Science Services, SIREN Interactive, and Red Arrow Software Labs. As the trusted partner to more than 700 BioPharma and MedTech innovators, Dohmen propels start-up, mid-tier and Fortune 500 companies with support services that span the commercialization continuum from pre-approval regulatory consulting to in-home patient services. Privately held and conflict free, Dohmen is uniquely positioned to propel personalized healthcare for life science innovators and individuals. Learn more about the Dohmen family of companies at www.dohmen.com
CONTACT: Tiffany Huth, email@example.com, 1-414-434-4691
SOURCE Dohmen Life Science Services